[1]
|
Middle East Cancer Consortium (MECC) Egypt, “The Gharbiah Population-Based Cancer Registry,” Ministry of Health and Populations Egypt and Middle East Cancer Consortium, Cairo, 1999.
|
[2]
|
National Cancer Institue, “Cairo University, Egypt. Cancer Registry 2002-2003,” National Cancer Institue, Cairo.
|
[3]
|
J. Hannemann, P. Kristel, H. van Tinteren, M. Bontenbal, Q. G. van Hoesel, W. M. Smit, et al., “Molecular Subtypes of Breast Cancer and Amplification of Topoisomerase II Alpha: Predictive Role in Dose Intensive Adjuvant Chemotherapy,” British Journal of Cancer, Vol. 95, No. 10, 2006, pp. 1334-41.
|
[4]
|
R. B. Dickson, R. G. Pestell and M. E. Lippman, “Cancer of the Breast,” In: V. Devita, S. Hellman and S. A. Rosenberg, Cancer Principles & Practice of Oncology, 7th Edition, Lippincott, Williams & Wilkins, Philadelphia, 2005, pp. 1595-1654.
|
[5]
|
R. A. Walker, J. M. Bartlett, M. Dowsett, I. O. Ellis, A. M. Hanby, B. Jasani, et al., “HER2 Testing in the UK: Further Update to Recommendations,” Journal of Clinical Pathology, Vol. 61, No. 7, 2008, pp. 818-824.
doi:10.1136/jcp.2007.054866
|
[6]
|
D. Varshney, Y. Y. Zhou, S. A. Geller and R. Alsabeh, “Determination of HER-2 Status and Chromosome 17 Polysomy in Breast Carcinomas Comparing HercepTest and PathVysion FISH Assay,” American Journal of Clinical Pathology, Vol. 121, No. 1, 2004, pp. 70-77.
doi:10.1309/FUQH92B039025LHG
|
[7]
|
H. J. Burstein, L. N. Harris, R. Gelman, S. C. Lester, R. A. Nunes, C. M. Kaelin, et al., “Preoperative Therapy with Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study,” Journal of Clinical Oncology, Vol. 21, No. 1, 2003, pp. 46-53.
|
[8]
|
M. F. Press, R. S. Finn, D. Cameron, A. Di Leo, C. E. Geyer, I. E. Villalobos, et al., “HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer,” Clinical Cancer Research, Vol. 14, No. 23, 2008, pp. 7861-7870.
|
[9]
|
P. L. Fitzgibbons, D. A. Murphy, D. M. Dorfman, P. C. Roche and R. R. Tubbs, “Interlaboratory Comparison of Immunohistochemical Testing for HER2: Results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey,” Archives of Pathology & Laboratory Medicine, Vol. 130, No. 10, 2006, pp. 1440-1445.
|
[10]
|
A. Rhodes, B. Jasani, E. Anderson, A. R. Dodson and A. J. Balaton, “Evaluation of HER-2/neu Immunohistochemical Assay Sensitivity and Scoring on Formalin-Fixed and Paraffin-Processed Cell Lines and Breast Tumors: A Comparative Study Involving Results from Laboratories in 21 Countries,” American Journal of Clinical Pathology, Vol. 11, No. 3, 2002, pp. 408-417.
|
[11]
|
M. B. Lambros, R. Natrajan and J. S. Reis-Filho, “Chromogenic and Fluorescent in Situ Hybridization in Breast Cancer,” Human Pathology, Vol. 38, No. 8, 2007, pp. 1105-1022. doi:10.1016/j.humpath.2007.04.011
|
[12]
|
M. F. Press, G. Sauter, L. Bernstein, I. E. Villalobos, M. Mirlacher, J. Y. Zhou, et al., “Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials,” Clinical Cancer Research, Vol. 11, No. 18, 2005, pp. 6598-6607.
|
[13]
|
H. Yaziji, L. C. Goldstein, T. S. Barry, R. Werling, H. Hwang, G. K. Ellis, et al., “HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods,” JAMA Network, Vol. 291, No. 16, 2004, pp. 1972-1977.
|
[14]
|
L. Arnould, P. Roger, G. Macgrogan, M. P. Chenard, A. Balaton, S. Beauclair, et al., “Accuracy of HER2 Status Determination on Breast Core-Needle Biopsies (Immunohistochemistry, FISH, CISH and SISH vs FISH),” Modern Pathology, Vol. 25, No. 5, 2012, pp. 675-682.
|
[15]
|
A. C. Wolff, M. E. Hammond, J. N. Schwartz, K. L. Hagerty, D. C. Allred, R. J. Cote, et al., “American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer,” Journal of Clinical Oncology, Vol. 25, No. 1, 2007, pp. 118-145.
doi:10.1200/JCO.2006.09.2775
|
[16]
|
I. O. Ellis, J. Bartlett, M. Dowsett, S. Humphreys, B. Jasani, K. Miller, et al., “Best Practice No 176: Updated Recommendations for HER2 Testing in the UK,” Journal of Clinical Pathology, Vol. 57, No. 3, 2004, pp. 233-237.
doi:10.1136/jcp.2003.007724
|
[17]
|
M. Abdel-Hadi, G. F. Abdel-Hamid, N. Abdel-Razek and R. K. Fawzy, “Should Fine-Needle Aspiration Cytology Be the First Choice Diagnostic Modality for Assessment of All Nonpalpablebreast Lesions? The Experience of a Breast Cancer Screening Center in Alexandria, Egypt,” Diagnostic Cytopathology, Vol. 38, No. 12, 2010, pp. 880-889. doi:10.1002/dc.21305
|
[18]
|
B. G. Beatty, R. Bryant, W. Wang, T. Ashikaga, P. C. Gibson, G. Leiman, et al., “HER-2/neu Detection in FineNeedle Aspirates of Breast Cancer: Fluorescence in Situ Hybridization and Immunocytochemical Analysis,” American Journal of Clinical Pathology, Vol. 122, No. 2, 2004, pp. 246-255.
|
[19]
|
C. Bozzetti, R. Nizzoli, A. Guazzi, M. Flora, C. Bassano, P. Crafa, et al., “HER-2/neu Amplification Detected by Fluorescence in Situ Hybridization in Fine Needle Aspirates from Primary Breast Cancer,” Annals of Oncology, Vol. 13, No. 9, 2002, pp. 1398-1403.
doi:10.1093/annonc/mdf217
|
[20]
|
A. Mezzelani, L. Alasio, C. Bartoli, M. G. Bonora, M. A. Pierotti, F. Rilke, et al., “c-erbB2/neu Gene and Chromosome 17 Analysis in Breast Cancer by FISH on Archival Cytological Fine-Needle Aspirates,” British Journal of Cancer, Vol. 80, No. 3-4, 1999, pp. 519-525.
|
[21]
|
D. T. McManus, A. H. Patterson, P. Maxwell, M. W. Humphreys and N. H. Anderson, “Fluorescence in Situ Hybridisation Detection of erbB2 Amplification in Breast Cancer Fine Needle Aspirates,” Molecular Pathology, Vol. 52, No. 2, 1999, pp. 75-77.
|
[22]
|
G. Sauter, G. Feichter, J. Torhorst, H. Moch, H. Novotna, U. Wagner, et al., “Fluorescence in Situ Hybridization for Detecting erbB-2 Amplification in Breast Tumor Fine Needle Aspiration Biopsies,” Acta Cytologica, Vol. 40, No. 2, 1996, pp. 164-173.
|
[23]
|
J. Klijanienko, J. Couturier, M. Galut, A. K. El-Naggar, Z. Maciorowski, E. Padoy, et al., “Detection and Quantitation by Fluorescence in Situ Hybridization (FISH) and Image Analysis of HER-2/neu Gene Amplification in Breast Cancer Fine-Needle Samples,” Cancer, Vol. 87, No. 5, 1999, pp. 312-318.
|
[24]
|
A. M. Gown, “Current Issues in ER and HER2 Testing by IHC in Breast Cancer,” Modern Pathology, Vol. 21, No. S8-S15, 2008, p. 34.
|
[25]
|
A. Thor, “Applications of Molecular Analysis to Small Biopsy and Cytology Specimens for Diagnosis and Targeted Therapy. HER2/neu (erbB2) Analysis on FNA Smears and Core Biopsies of Primary or Metastatic Breast Cancer,” PSC/USCAP, 2008.
http://pathologyportal.org/97th/pdf/comp anion16h03.pdf
|
[26]
|
M. F. Press, D. J. Slamon, K. J. Flom, J. Park, J. Y. Zhou and L. Bernstein, “Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens,” Journal of Clinical Oncology, Vol. 20, No. 14, 2002, pp. 3095-3105.
|
[27]
|
K. I. Goud, S. Dayakar, K. Vijayalaxmi, S. J. Babu and P. V. Reddy, “Evaluation of HER-2/neu Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) & Fluorescence In-Situ Hybridization (FISH) Assay,” Indian Journal of Medical Research, Vol. 135, No. 3, 2012, pp. 312-317.
|
[28]
|
R. D. Mass, M. F. Press and S. Anderson, “Improved Survival Benefit from Herceptin (Trastuzumab) in Patients Selected by Fluorescence in Situ Hybridization (FISH) (Abstract),” Proc Am Soc Clin Oncol, Vol. 20, No. 22a, 2001.
|
[29]
|
S. Kakar, N. Puangsuvan, J. M. Stevens, R. Serenas, G. Mangan, S. Sahai, et al., “HER-2/neu Assessment in Breast Cancer by Immunohistochemistry and Fluorescence in Situ Hybridization: Comparison of Results and Correlation with Survival,” Journal of Molecular Diagnostics, Vol. 5, No. 3, 2000, pp. 199-207.
|
[30]
|
M. F. Press, L. Bernstein, P. A. Thomas, L. F. Meisner, J. Y. Zhou, Y. Ma, et al., “HER-2/neu Gene Amplification Characterized by Fluorescence in Situ Hybridization: Poor Prognosis in Node-Negative Breast Carcinomas,” Journal of Clinical Oncology, Vol. 15, No. 8, 1997, pp. 2894-2904.
|
[31]
|
G. Pauletti, S. Dandekar, H. Rong, L. Ramos, H. Peng, R. Seshadri, et al., “Assessment of Methods for TissueBased Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence in Situ Hybridization and Immunohistochemistry,” Journal of Clinical Oncology, Vol. 18, No. 21, 2000, pp. 3651-3664.
|
[32]
|
C. L. Vogel, M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, et al., “Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer,” Journal of Clinical Oncology, Vol. 20, No. 3, 2002, pp. 719-726.
|
[33]
|
M. A. Cobleigh, C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, et al., “Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed after Chemotherapy for Metastatic Disease,” Journal of Clinical Oncology, Vol. 17, No. 9, 1999, pp. 2639-2648.
|
[34]
|
T. W. Jacobs, A. M. Gown, H. Yaziji, M. J. Barnes and S. J. Schnitt, “Specificity of HercepTest in determining HER2/neu Status of Breast Cancers Using the United States Food and Drug Administration-Approved Scoring System,” Journal of Clinical Oncology, Vol. 17, No. 7, 1999, pp. 1983-1987.
|
[35]
|
P. C. Roche and J. N. Ingle, “Increased HER2 with US Food and Drug Administration-Approved Antibody,” Journal of Clinical Oncology, Vol. 17, No. 1, 1999, p. 434.
|
[36]
|
A. Lebeau, D. Deimling, C. Kaltz, A. Sendelhofert, A. Iff, B. Luthardt, et al., “Her-2/neu Analysis in Archival Tissue Samples of Human Breast Cancer: Comparison of Immunohistochemistry and Fluorescence in Situ Hybridization,” Journal of Clinical Oncology, Vol. 19, No. 2, 2001, pp. 354-363.
|